Your shopping cart is currently empty

Xanomeline oxalate (LY246708 oxalate), a potent and selective muscarinic receptor agonist (SMRA), effectively stimulates in vivo phosphoinositide hydrolysis. It is a valuable compound for Alzheimer's disease research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $32 | In Stock | In Stock | |
| 10 mg | $53 | In Stock | In Stock | |
| 25 mg | $107 | In Stock | In Stock | |
| 50 mg | $171 | In Stock | In Stock | |
| 100 mg | $272 | In Stock | In Stock | |
| 200 mg | $392 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $35 | In Stock | In Stock |
| Description | Xanomeline oxalate (LY246708 oxalate), a potent and selective muscarinic receptor agonist (SMRA), effectively stimulates in vivo phosphoinositide hydrolysis. It is a valuable compound for Alzheimer's disease research. |
| In vitro | Xanomeline stimulates phosphoinositide (PI) hydrolysis in A9 L m1 cells and inhibits [3H]-PZ and [3H]-OXO-M binding to rat brain, with Kis of 7 and 3 nM, respectively[1]. |
| In vivo | Xanomeline robustly stimulates in vivo PI hydrolysis, an effect blocked by muscarinic antagonists, indicating mediation by muscarinic receptors. In mice, the ED100 for Xanomeline-induced stimulation of [3H]-IP accumulation in the hippocampus is 54 μmole/kg, while in rats, it is 8.1 μmole/kg in the hippocampus[1]. |
| Synonyms | LY246708 oxalate |
| Molecular Weight | 371.45 |
| Formula | C16H25N3O5S |
| Cas No. | 141064-23-5 |
| Smiles | OC(=O)C(O)=O.CCCCCCOc1nsnc1C1=CCCN(C)C1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (121.15 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.38 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.